Hunan Jiudian Pharmaceutical Co Ltd (300705) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has a cash flow conversion efficiency ratio of 0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥180.33 Million ≈ $26.39 Million USD) by net assets (CN¥2.66 Billion ≈ $388.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hunan Jiudian Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300705 current and long-term liabilities for a breakdown of total debt and financial obligations.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
0.011x |
|
Rongan Property Co Ltd
SHE:000517
|
0.055x |
|
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A
SHE:300767
|
0.030x |
|
Clean Science and Technology Limited
NSE:CLEAN
|
0.015x |
|
AMG Advanced Metallurgical Group NV
AS:AMG
|
-0.018x |
|
Insperity Inc
NYSE:NSP
|
-6.043x |
|
Sino-High (China) Co. Ltd.
SHE:301076
|
N/A |
|
Sichuan Jiuyuan Yinhai Software Co Ltd
SHE:002777
|
0.047x |
Annual Cash Flow Conversion Efficiency for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Hunan Jiudian Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.53 Billion ≈ $369.74 Million |
CN¥746.36 Million ≈ $109.22 Million |
0.295x | +35.18% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.75 Million |
CN¥431.19 Million ≈ $63.10 Million |
0.219x | +26.13% |
| 2022-12-31 | CN¥1.55 Billion ≈ $227.20 Million |
CN¥268.99 Million ≈ $39.36 Million |
0.173x | -0.22% |
| 2021-12-31 | CN¥1.10 Billion ≈ $160.87 Million |
CN¥190.87 Million ≈ $27.93 Million |
0.174x | -3.27% |
| 2020-12-31 | CN¥835.68 Million ≈ $122.29 Million |
CN¥149.99 Million ≈ $21.95 Million |
0.179x | +50.70% |
| 2019-12-31 | CN¥761.87 Million ≈ $111.49 Million |
CN¥90.74 Million ≈ $13.28 Million |
0.119x | +25.36% |
| 2018-12-31 | CN¥718.16 Million ≈ $105.09 Million |
CN¥68.23 Million ≈ $9.98 Million |
0.095x | -21.99% |
| 2017-12-31 | CN¥660.26 Million ≈ $96.62 Million |
CN¥80.42 Million ≈ $11.77 Million |
0.122x | -28.61% |
| 2016-12-31 | CN¥323.43 Million ≈ $47.33 Million |
CN¥55.18 Million ≈ $8.07 Million |
0.171x | +34.88% |
| 2015-12-31 | CN¥254.51 Million ≈ $37.24 Million |
CN¥32.20 Million ≈ $4.71 Million |
0.126x | -11.82% |
| 2014-12-31 | CN¥209.87 Million ≈ $30.71 Million |
CN¥30.11 Million ≈ $4.41 Million |
0.143x | -17.81% |
| 2013-12-31 | CN¥175.85 Million ≈ $25.73 Million |
CN¥30.69 Million ≈ $4.49 Million |
0.175x | -- |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more